Follicular thyroid cancer surgery: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 14: Line 14:
** [[Invasive]] (extensive [[vascular]] [[invasion]] is present)
** [[Invasive]] (extensive [[vascular]] [[invasion]] is present)
** [[Metastatic]]
** [[Metastatic]]
** Patients'preference is another indication.  
* Patients'preference is another indication.  
* Unilateral hemithyroidectomy is uncommon due to the aggressive nature of follicular thyroid cancer.<ref> Thyroid Cancer Cancer.gov
* Unilateral hemithyroidectomy is uncommon due to the aggressive nature of follicular thyroid cancer.<ref> Thyroid Cancer Cancer.gov
(2015). http://www.cancer.gov/types/thyroid/hp/thyroid-treatment-pdq#section/_6- Accessed on October, 29 2015</ref>
(2015). http://www.cancer.gov/types/thyroid/hp/thyroid-treatment-pdq#section/_6- Accessed on October, 29 2015</ref>

Revision as of 16:07, 18 October 2019

Follicular thyroid cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Follicular thyroid cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Follicular thyroid cancer surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Follicular thyroid cancer surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Follicular thyroid cancer surgery

CDC on Follicular thyroid cancer surgery

Follicular thyroid cancer surgery in the news

Blogs on Follicular thyroid cancer surgery

Directions to Hospitals Treating Follicular thyroid cancer

Risk calculators and risk factors for Follicular thyroid cancer surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Surgery is the mainstay of treatment for follicular thyroid cancer.

Surgery

Indications

  • Lobectomy plus isthmusectomy is indicated when the tumor is minimally invasive.[1]
  • Total thyroidectomy is indicated when the tumor is:
  • Patients'preference is another indication.
  • Unilateral hemithyroidectomy is uncommon due to the aggressive nature of follicular thyroid cancer.[2]
  • Total thyroidectomy is the mainstay of treatment for follicular thyroid cancer. This is invariably followed by radioiodine treatment at levels from 50 to 200 millicuries following two weeks of a low iodine diet (LID). Occasionally treatment must be repeated if annual scans indicate remaining cancerous tissue.

Stage I and II Follicular Thyroid Cancer

Total Thyroidectomy

  • The objective of surgery is to completely remove the primary tumor while minimizing treatment-related morbidity and to guide postoperative treatment with radioactive iodine (RAI). The goal of radioactive iodine (RAI) is to ablate the remnant thyroid tissue to improve the specificity of thyroglobulin assays, which allows the detection of persistent disease by follow-up whole-body scanning. For patients undergoing radioactive iodine (RAI), removal of all normal thyroid tissue is an important surgical objective. Additionally, for accurate long-term surveillance, radioactive iodine (RAI) whole-body scanning and measurement of serum thyroglobulin are affected by residual, normal thyroid tissue, and in these situations, near-total or total thyroidectomy is required. This approach facilitates follow-up thyroid scanning.

Lobectomy

  • Lobectomy is associated with a lower incidence of complications, but approximately 5% to 10% of patients will have a recurrence in the thyroid following lobectomy. Patients younger than 45 years will have the longest follow-up period and the greatest opportunity for recurrence. Follicular thyroid cancer commonly metastasizes to lungs and bone; with a remnant lobe in place, use of I-131 as ablative therapy is compromised. Abnormal regional lymph nodes should be biopsied at the time of surgery. Recognized nodal involvement should be removed at initial surgery, but selective node removal can be performed, and radical neck dissection is usually not required. This results in a decreased recurrence rate but has not been shown to improve survival.
  • Following the surgical procedure, patients should receive postoperative treatment with exogenous thyroid hormone in doses sufficient to suppress thyroid-stimulating hormone (TSH); studies have shown a decreased incidence of recurrence when thyroid-stimulating hormone is suppressed.

Stage III Follicular Thyroid Cancer

Standard Treatment Options

Stage IV Follicular Thyroid Cancer

Lymph Node Metastasis

  • For lymph node metastasis, central neck dissection is recommended.
  • Central neck dissection includes the evacuation of fibrofatty and nodal tissue from the common carotid artery to hyoid bones superiorly and inferiorly up to the innominate artery.
  • Modified neck dissection is reserved for lymph nodes with macroscopic metastasis. In this procedure, all nodal and fibrofatty tissues are removed from levels II to level V in the neck.

Bone Metastasis

Reference

  1. 1.0 1.1 "www.nccn.org" (PDF).
  2. Thyroid Cancer Cancer.gov (2015). http://www.cancer.gov/types/thyroid/hp/thyroid-treatment-pdq#section/_6- Accessed on October, 29 2015